Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM602 in Acute Ischemic Stroke
NCT01221246Phase 2Completed
- Sponsor
- Genervon Biopharmaceuticals
- Start
- Mar 2011
- Primary completion
- Jul 2016
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of alirinetide in ischemic stroke, sponsored by Genervon Biopharmaceuticals. Started Mar 2011; status: completed.
02
Drugs
alirinetide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT01221246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01221246.